Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma.
Clin Nucl Med
; 49(6): 584-586, 2024 Jun 01.
Article
em En
| MEDLINE
| ID: mdl-38630998
ABSTRACT
ABSTRACT A 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
/
Lutécio
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Clin Nucl Med
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
França